Latest Presentations
R&D Day 2018 New York
December 6, 2018
MP Corporate Presentation
December 6, 2018
Products
Molecular Partners is advancing a growing pipeline of DARPin therapies for the treatment of severe or life-threatening diseases, with an initial focus on oncology and ophthalmology. Its most advanced oncology candidate, MP0250, is for the treatment of solid tumors and hematological malignancies. In ophthalmology, the most advanced candidate is abicipar in wet age-related macular degeneration (wet AMD). It has been licensed to Allergan and is being tested in two phase 3 trials.
We tailor each DARPin® therapy to target single or multiple disease pathways responsible for serious and complex diseases, all in a single medicine.
